-
-
-
-
-
-
-
Incannex Healthcare forms clinical advisory board for PSX-001 program
-
-
-
-
-
-
-
Incannex Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
-
-
-
-
-
-
-
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
-
-
-
-
-
-
-
Incannex Healthcare (IXHL) achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X
-
-
-
-
-
-
-
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
-
-
-
-
-
-
-
Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
-
-
-
-
-
-
-
Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates
-
1,198,729 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

